Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma Group (MREO) Cash & Current Investments: 2020-2025

Historic Cash & Current Investments for Mereo BioPharma Group (MREO) over the last 2 years, with Sep 2025 value amounting to $48.7 million.

  • Mereo BioPharma Group's Cash & Current Investments fell 39.52% to $48.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $237.1 million, marking a year-over-year decrease of 13.48%. This contributed to the annual value of $69.8 million for FY2024, which is 21.56% up from last year.
  • As of Q3 2025, Mereo BioPharma Group's Cash & Current Investments stood at $48.7 million, which was down 13.23% from $56.1 million recorded in Q2 2025.
  • Mereo BioPharma Group's Cash & Current Investments' 5-year high stood at $153.9 million during Q2 2021, with a 5-year trough of $48.7 million in Q1 2024.
  • For the 3-year period, Mereo BioPharma Group's Cash & Current Investments averaged around $63.9 million, with its median value being $60.0 million (2023).
  • In the last 5 years, Mereo BioPharma Group's Cash & Current Investments spiked by 310.18% in 2021 and then slumped by 46.36% in 2022.
  • Mereo BioPharma Group's Cash & Current Investments (Quarterly) stood at $127.1 million in 2021, then slumped by 46.36% to $68.2 million in 2022, then decreased by 15.78% to $57.4 million in 2023, then rose by 21.56% to $69.8 million in 2024, then tumbled by 39.52% to $48.7 million in 2025.
  • Its last three reported values are $48.7 million in Q3 2025, $56.1 million for Q2 2025, and $62.5 million during Q1 2025.